Osaka, Japan

Toshinaga Tsuji

USPTO Granted Patents = 2 

 


Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Sapporo, JP (2013)
  • Osaka, JP (2015)

Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Toshinaga Tsuji: Pioneering Monoclonal Antibodies

Introduction

Toshinaga Tsuji, an accomplished inventor based in Osaka, Japan, has made significant contributions to the field of biotechnology. With two notable patents to his name, Tsuji's work focuses on the development of humanized antibodies that target specific infections, particularly those caused by Pseudomonas aeruginosa. His innovative approach has the potential to enhance therapeutic outcomes in treating serious infections.

Latest Patents

Tsuji's latest patents include the "Humanized PcrV antibody having anti-pseudomonal activity" and "Antibody against PcrV." These inventions describe a humanized monoclonal antibody designed to inhibit cytotoxicity in target cells affected by PcrV, which is crucial in managing infections. The humanized monoclonal antibody boasts high affinity for PcrV, making it an effective component in pharmaceutical compositions aimed at combating infections.

Career Highlights

Toshinaga Tsuji is associated with Shionogi & Company Limited, where he collaborates with a dedicated team to advance research in monoclonal antibodies. His relentless pursuit of innovation has led to breakthroughs in antibody development, pushing the boundaries of therapeutic applications in combating infectious diseases.

Collaborations

Throughout his career, Tsuji has worked alongside esteemed colleagues, including Yoshito Numata and Yoshinori Yamano. These collaborations have fostered a dynamic research environment, facilitating the exchange of ideas and expertise, ultimately leading to the successful development of innovative antibody therapies.

Conclusion

Toshinaga Tsuji stands out as an innovative force in biomedicine, contributing to the advancement of monoclonal antibody therapies. His patents reflect a commitment to addressing pressing health challenges through scientific ingenuity. As research progresses, Tsuji's work will likely spearhead new avenues of treatment for infections caused by Pseudomonas aeruginosa, solidifying his legacy as an influential inventor in his field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…